The foundation of our corporate culture is the awareness of the social value of plasma processing for the treatment of extremely severe and debilitating diseases, such as haemophilia and immune deficiencies.

We invest in people, innovation and research to support the medical and scientific communities and the institutional patient communities worldwide, for ongoing product and process improvement, to give our contribution to making treatments widely available.